Pelthos director Ezra Friedberg sells 558 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Ezra M. Friedberg, a director of Pelthos Therapeutics Inc. (PTHS), sold 558 shares of common stock on October 2, 2026, at $20.7169 per share under a Rule 10b5-1 plan adopted December 16, 2025, to satisfy estimated tax obligations tied to vesting of issuer-granted restricted stock units. He directly held 80,484 shares afterward.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1 | 558 | $20.7169 | $12K |
| holding | Common Stock F2 | -- | -- | -- |
| holding | Common Stock F2 | -- | -- | -- |
Footnotes (2)
- F1. This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.
- F2. Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.
Key Figures
Key Terms
Rule 10b5-1 plan regulatory
restricted stock units financial
pecuniary interest financial
beneficially own financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.